JD-010 is under clinical development by Beijing JD Biotech and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I drugs for Hematological Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the JD-010 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JD-010 overview

JD-010 is under development for the treatment of refractory or relapsed B-cell hematologic malignancies. It is administered through intravenous route. The therapy comprises of allogeneic NK cells genetically engineered to express chimeric antigen receptors (CAR) targeting cells expressing B lymphocyte antigen CD19.

Beijing JD Biotech overview

Beijing JD Biotech (JD Biotech) is an biotechnology company which is specialized to provide development and research of immune cells to produce medicine and offers other related services. JD Biotech is headquartered in Beijing, China.

For a complete picture of JD-010’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.